Business Description
LadRx Corp
NAICS : 325414
SIC : 2836
ISIN : US2328286081
Description
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 60.71 | |||||
Equity-to-Asset | 0.16 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 6/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 26.4 | |||||
3-Year EPS without NRI Growth Rate | 31.7 | |||||
3-Year Book Growth Rate | -79.3 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.18 | |||||
Quick Ratio | 1.18 | |||||
Cash Ratio | 1.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.7 | |||||
Shareholder Yield % | 13.53 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | 399.52 | |||||
ROA % | 64.89 | |||||
ROIC % | -1918.45 | |||||
ROC (Joel Greenblatt) % | -3921.05 | |||||
ROCE % | -859.2 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 0.77 | |||||
PE Ratio without NRI | 0.77 | |||||
Price-to-Owner-Earnings | 0.77 | |||||
PEG Ratio | 0.04 | |||||
PB Ratio | 3.62 | |||||
Price-to-Tangible-Book | 2.8 | |||||
Price-to-Free-Cash-Flow | 0.71 | |||||
Price-to-Operating-Cash-Flow | 0.71 | |||||
EV-to-EBIT | 0.22 | |||||
EV-to-EBITDA | 0.22 | |||||
EV-to-FCF | -0.46 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.04 | |||||
Price-to-Graham-Number | 0.35 | |||||
Price-to-Net-Current-Asset-Value | 2.8 | |||||
Price-to-Net-Cash | 5.6 | |||||
Earnings Yield (Greenblatt) % | 455.18 | |||||
FCF Yield % | 137.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LadRx Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | 3.006 | ||
Beta | 1.44 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 0.056 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 0.056 - 0.056 | ||
Shares Outstanding (Mil) | 0.5 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
LadRx Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
LadRx Corp Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
LadRx Corp Frequently Asked Questions
What is LadRx Corp(STU:CX5)'s stock price today?
The current price of STU:CX5 is €0.06. The 52 week high of STU:CX5 is €0.06 and 52 week low is €0.06.
When is next earnings date of LadRx Corp(STU:CX5)?
The next earnings date of LadRx Corp(STU:CX5) is 2024-08-14 Est..
Does LadRx Corp(STU:CX5) pay dividends? If so, how much?
LadRx Corp(STU:CX5) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |